Republican leaders on the House Energy & Commerce Committee want answers from FDA by Monday (July 8) on why there is so much variability in the agency’s foreign inspections, telling FDA in a recent letter they question the skill levels and integrity of the agency’s inspectorate and are probing whether some employees conducting oversight of Chinese and Indian facilities may have been unduly influenced or even accepted bribes, though they don’t provide evidence. The lawmakers wrote to FDA on June...